Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Contraindicates Three Gadolinium Imaging Agents In Severe Kidney Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

However, the agency says all seven gadolinium-based contrast agents used in MRI and MRA procedures present a risk of nephrogenic systemic fibrosis.

You may also be interested in...



FDA Forgoes Sponsor Support In Safety Study Of Contrast Agents To Avoid Potential Bias

Instead of requiring sponsors to conduct a study, the agency is providing grant to the University of Pittsburgh Medical Center to create a prospective registry that will examine the relationship between exposure to gadolinium-based contrast agents and nephrogenic systemic fibrosis.

Zyvox Drug Interactions Draw Second Safety Communication From FDA, But Pfizer Says Info Isn't New

FDA and Pfizer appear to disagree over whether new information about harmful drug interactions between Pfizer’s antibiotic Zyvox (linezolid) and serotonergic antidepressants, including multiple deaths, led the agency to issue a drug safety communication.

Zyvox Drug Interactions Draw Second Safety Communication From FDA, But Pfizer Says Info Isn't New

FDA and Pfizer appear to disagree over whether new information about harmful drug interactions between Pfizer’s antibiotic Zyvox (linezolid) and serotonergic antidepressants, including multiple deaths, led the agency to issue a drug safety communication.

Related Content

Topics

UsernamePublicRestriction

Register

PS071281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel